The purpose of this research study is to compare overall survival and to compare the effects (good and bad) of stereotactic radiosurgery (SRS) to whole brain radiation therapy (WBRT) on the subject and their brain metastases.
To be eligible, the results of the MRI must show that the subject have at least one but no more than four brain metastases with one of the brain metastases resected. The study doctor must also verify that the subject meets other study requirements, such as not being pregnant. If the subjects are eligible and agree to participate, they will be randomized into one of the two treatment groups. The two treatment groups are: (Group A) whole brain radiation therapy (WBRT) and (Group B) stereotactic radiosurgery (SRS)
The study team would like to keep track of the subjects medical condition as long as the subject is alive or for a maximum of five years after the subject begins this study to look for any long-term effects of the treatment in this study.
The purpose of this project is to test the accuracy, acceptability and overall performance of a smart phone surveillance application (app) that is being developed to help prevent preterm birth. The smart phone app will measure contractions of pregnant women who are in labor. The results of the smart phone app will be compared with the results that are taken by the traditional machine that is used to measure contractions for women who are in labor.
To encourage women with Fibromyalgia to engage in physical activity using text messaging as means of encouragement. This is a 12 week study the will utilize various stretching exercises along with a pedometer to increase daily physical activity. Subjects will keep a daily diary of there activity, pain, and sleep and complete on-line questionnaires at the beginning and end of the study.
This is a multicenter, observational study.
This research study will test whether the methods being developed for the detection of fetal aneuploidy from samples of maternal blood can be used in the laboratory and employed in clinical practice
This study is for patients that have a brain tumor, called a glioblastoma or gliosarcoma, which has become worse after previous treatment. The purpose of this study is to determine whether adding radiation to bevacizumab is more effective than using bevacizumab alone to treat recurrent glioblastomas.
In this trial patients will be randomly assigned to receive either bevacizumab alone or bevacizumab and radiation therapy.If you are in Group 1, you will be asked to take bevacizumab alone every two weeks as long as it is working and there are no intolerable side effects. If patients are assigned to Group 2, he/she will take bevacizumab 2 weeks before radiation therapy, during radiation therapy, and then every 2 weeks after radiation therapy as long as it is working and there are no intolerable side effects. The radiation will be given to participants over 2 weeks. Participants will be followed every 8 weeks while on treatment and then also if participants are removed from protocol treatment. Follow-up will continue every 8 weeks for 1 year, then every 6 months for 1 year, then annually.
The goal of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control a suhbjects glioblastoma. The safety of this drug combination will also be studied.
Pazopanib is FDA approved and commercially available for the treatment of renal cell cancer. Topotecan is FDA approved and commercially available for the treatment of lung cancer. In this study, the combination of pazopanib and topotecan is being used for research purposes only.
Up to 66 participants will be enrolled in this multicenter study. About 5 of those patients will be enrolled at MUSC under the care Dr. Giglio, MD.
This study if for patients that have been diagnosed with muliple myeloma. Pharmacyclics, Inc. (the Sponsor) is studying an investigational new drug called ibrutinib. Ibrutinib is a type of drug called a “kinase inhibitor”. “Kinases” are proteins inside cells that help cells live and grow. The specific kinase inhibited or “blocked” by ibrutinib is believed to help blood cancer cells live and grow. By inhibiting the activity of this specific kinase, it is possible that the ibrutinib may kill the cancer cells or stop them from growing.
The study has two parts:
• Phase 1 tests different doses of ibrutinib and carfilzomib together to study what dose to use in Phase 2b
• Phase 2b will study the effects of the treatment. All subjects will receive carfilzomib, only half of the subjects will receive ibrutinib, to test if there is a benefit to adding ibrutinib to carfilzomib treatment
Participation in this study will last approximately two years. This will include coming to the study center for treatment and follow-up after the study treatment ends.
This study is for subjects with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has returned after treatment or did not respond to earlier treatment. The purpose of this study is to compare pegylated liposomal doxorubicin (PLD; a standard chemotherapy) to PLD in combination with VTX-2337 (a new type of drug that stimulates the immune system) to see if it helps cancer tumors stop growing or shrink, and if it helps women with these types of cancer live longer. PLD is an FDA-approved treatment for women with ovarian cancer. In prior studies, approximately 15–20% of women who received PLD for relapsed ovarian cancer experienced a temporary shrinkage or disappearance of their tumor. VTX 2337 is an experimental drug (not approved by the Food and Drug Administration, FDA) that stimulates the immune system and may help the body kill cancer cells. The combination of PLD plus VTX-2337 has been evaluated in a previous study of 13 patients. The study is still ongoing, but so far there is evidence that PLD + VTX-2337 may temporarily stop some patients’ tumors from growing (this happened in 6 patients), or it may help cancer tumors temporarily shrink and/or disappear (this happened in 1 patient).
In addition to the treatment part of this study, the researchers plan to test samples of your tumor and some of your blood. You cannot participate in this study if you do not agree to provide these specimens for this research. The purpose of this research is to examine the impact the study drugs have on tumor tissue and specific blood cells and substances.
Lastly, researchers want to know if one's genes (DNA) affect how the body responds to the experimental medication or how one's body breaks it down. Subjects will receive the study drugs as long as there is evidence that their tumor is not growing and they are not experiencing unacceptable side effects.
This study is for patients suspected of having Mast Cell Activation Syndrome (MCAS). MCAS is a state in which some portion of the body’s mast cells – which ordinarily produce many different signals influencing other cells to alter their behavior so as to maintain a state of health – produce signals which are abnormal in their intensity, duration, and/or location in the body, potentially causing a wide variety of acute and chronic symptoms and complications.
This research study seeks to understand how many mast cells are circulating in the blood of MCAS patients and whether there are increased blood levels in MCAS patients of certain signals which cause increases in certain types of white blood cells which commonly are seen in excess in MCAS patients.
This study will compare how bladder cancer responds to treatment with one of three regimens docetaxel, docetaxel with ramucirumab DP or docetaxel with IMC-18F1. The response to treatment will be measured by the length of time on assigned arm before the disease progresses. The study will also look at how long the tumor stays the same size, or in the event of a decrease in tumor size, how long the decrease in tumor size continues. The study will also look at the side effects of the chemotherapy arm compared with the side effects of chemotheapy combined with either investigational agent. The study will also gather information on the levels of ramucirumab DP or IMC-18F1 in the blood.